Everence Capital Management Inc Nektar Therapeutics Transaction History

Everence Capital Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 31, 2023	SELL	$2.03 - $4.28 $36,357 - $76,654	-17,910 Reduced 37.57%	29,760 $67,000
Q2 2022 Jul 26, 2022	BUY	$3.17 - $6.17 $94,370 - $183,680	29,770 Added 166.31%	47,670 $181,000
Q1 2022 Apr 11, 2022	BUY	$4.16 - $13.72 $74,464 - $245,588	17,900 New	17,900 $96,000
Q1 2018 Apr 30, 2018	SELL	$57.4 - $108.44 $582,610 - $1.1 Million	-10,150 Closed	0 $0
Q3 2017 Oct 31, 2017	BUY	$17.79 - $24.0 $180,568 - $243,600	10,150	10,150 $244,000

153

131M

92.7K

4.9K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $161M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Everence Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Everence Capital Management Inc with notifications on news.